Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

BACKGROUND Neuroleptic-induced tardive dyskinesia (TD) is a major iatrogenic disorder that is more prevalent among older patients. The objective of this study was to determine the incidence of and risk factors for TD in neuroleptic-treated patients over age 45 years. METHODS We studied 266 middle-aged and elderly outpatients with a median duration of 21 days of total lifetime neuroleptic exposure at study entry. Most patients were treated throughout the study with either a high-potency or a low-potency neuroleptic and maintained on relatively low doses. The patients were followed up at 1- to 3-month intervals with "blind" assessment of psychopathologic condition, clinically as well as instrumentally (ie, using electromechanical sensors with computerized data reduction, including spectral analysis) evaluated movement disorder, and global cognitive function. RESULTS Cumulative incidence of TD was 26%, 52%, and 60% after 1, 2, and 3 years, respectively. The principal risk factors for TD were duration of prior neuroleptic use at baseline, cumulative amount of high-potency neuroleptics, history of alcohol abuse/dependence, borderline or minimal dyskinesia, and tremor on instrumental assessment. CONCLUSION Use of higher amounts of neuroleptics, particularly high-potency ones, should be avoided in older patients, patients with alcohol abuse/dependence, or patients with a subtle movement disorder at baseline; these patients are at a higher risk of developing TD.

[1]  D. Jeste,et al.  Neuroleptic withdrawal in schizophrenic patients. A review of the literature. , 1995, Archives of general psychiatry.

[2]  D. Jeste,et al.  Considering neuroleptic maintenance and taper on a continuum. Need for individual rather than dogmatic approach. , 1995, Archives of general psychiatry.

[3]  D. Collett Modelling Survival Data in Medical Research , 1994 .

[4]  S. Marder,et al.  Risperidone in the treatment of schizophrenia. , 1994, The American journal of psychiatry.

[5]  W. Glazer,et al.  Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. , 1993, Archives of general psychiatry.

[6]  S Pollack,et al.  Does clozapine cause tardive dyskinesia? , 1993, The Journal of clinical psychiatry.

[7]  J. Lieberman,et al.  Diabetes and development of tardive dyskinesia. , 1993, The American journal of psychiatry.

[8]  D. Greenberg Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association , 1993 .

[9]  J. Growdon,et al.  Electrophysiologic detection of extrapyramidal motor signs in Alzheimer's disease , 1993, Neurology.

[10]  J. Concato,et al.  The Risk of Determining Risk with Multivariable Models , 1993, Annals of Internal Medicine.

[11]  G. Barbato,et al.  Persistent tardive dyskinesia: demographic and pharmacological risk factors , 1993, Acta psychiatrica Scandinavica.

[12]  D. Jeste,et al.  Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus. Two case reports. , 1992, General hospital psychiatry.

[13]  J. Lohr,et al.  Quantitative instrumental measurement of tardive dyskinesia: a review. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[14]  J. Sweeney,et al.  Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. , 1992, Comprehensive psychiatry.

[15]  J. Lieberman,et al.  Prospective study of tardive dyskinesia incidence in the elderly. , 1991, JAMA.

[16]  D. Jeste,et al.  Instrumental evidence that age increases motor instability in neuroleptic-treated patients. , 1991, Journal of gerontology.

[17]  M. Menza,et al.  Smoking and movement disorders in psychiatric patients , 1991, Biological Psychiatry.

[18]  N. Cutler,et al.  Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients. , 1991, Hospital & community psychiatry.

[19]  L. Ganzini,et al.  The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. , 1991, Archives of general psychiatry.

[20]  D. Jeste,et al.  Clinical and instrumental assessment of neuroleptic-induced parkinsonism in patients with tardive dyskinesia , 1991, Biological Psychiatry.

[21]  G. Bartzokis,et al.  Effects of Anticholinergic Agents on Patients with Tardive Dyskinesia and Concomitant Drug‐Induced Parkinsonism , 1989, Journal of clinical psychopharmacology.

[22]  A. Rifkin,et al.  Changing patterns of neuroleptic dosage over a decade. , 1989, The American journal of psychiatry.

[23]  W. P. Dixon,et al.  BMPD statistical software manual , 1988 .

[24]  G. Gardos,et al.  The natural history of tardive dyskinesia. , 1988, Journal of clinical psychopharmacology.

[25]  L. Weinrauch,et al.  Metoclopramide-induced neuroleptic malignant syndrome. , 1987, Archives of internal medicine.

[26]  T. Craig,et al.  Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. , 1987, The American journal of psychiatry.

[27]  S. Lal,et al.  Nicotine exposure and tardive dyskinesia , 1987, Biological Psychiatry.

[28]  R. Baldessarini,et al.  Dissimilar dosing with high-potency and low-potency neuroleptics. , 1984, The American journal of psychiatry.

[29]  D. Jeste,et al.  Understanding and Treating Tardive Dyskinesia , 1982 .

[30]  J. Kane,et al.  Research diagnoses for tardive dyskinesia. , 1982, Archives of general psychiatry.

[31]  Wyatt Rj Biochemistry and schizophrenia (part IV) the neuroleptics--their mechanism of action: a review of the biochemical literature. , 1976 .

[32]  M. Alpert,et al.  Tremographic studies in tardive dyskinesia. , 1976, Psychopharmacology bulletin.

[33]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[34]  G. Crane Pseudoparkinsonism and tardive dyskinesia. , 1972, Archives of neurology.

[35]  N. Breslow A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship , 1970 .

[36]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[37]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[38]  F. Ederer,et al.  Maximum utilization of the life table method in analyzing survival. , 1958, Journal of chronic diseases.

[39]  Jane S. Paulsen,et al.  Neuropsychological impairment in Tardive dyskinesia. , 1994 .

[40]  D. Jeste,et al.  Treatment of late-life schizophrenia with neuroleptics. , 1993, Schizophrenia bulletin.

[41]  D. Jeste,et al.  High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. , 1992, Psychopharmacology bulletin.

[42]  D. Jeste,et al.  Gender differences in tardive dyskinesia: a critical review of the literature. , 1992, Schizophrenia bulletin.

[43]  M. Kiefer,et al.  Tardive dyskinesia in psychiatric patients with substance use disorders. , 1990, The American journal of drug and alcohol abuse.

[44]  Lohr Jb,et al.  Fine force instability: a quantitative measure of neuroleptic-induced dyskinesia in the hand. , 1990 .

[45]  Martin H. Teicher,et al.  Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. , 1988, Archives of general psychiatry.

[46]  J. Overall The brief psychiatric rating scale (BPRS) : Recent developments in ascertainment and scaling. Introduction , 1988 .

[47]  C. De Affective disorders and tardive dyskinesia. , 1988 .

[48]  G. Chouinard,et al.  Factors related to tardive dyskinesia. , 1979, The American journal of psychiatry.

[49]  D. Cox Regression Models and Life-Tables , 1972 .